Amyloidosis laboratory findings

	Amyloidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification • Primary amyloidosis • Secondary amyloidosis • Familial amyloidosis • Wild-type (senile) amyloidosis • Cardiac amyloidosis • Beta-2 microglobulin related amyloidosis • Gelsolin related amyloidosis • Lysozyme amyloid related amyloidosis • Leucocyte cell-derived chemotaxin 2 related amyloidosis • Fibrinogen A alpha-chain associated amyloidosis
Pathophysiology
Causes
Differentiating Amyloidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Amyloidosis laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Amyloidosis laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Amyloidosis laboratory findings
CDC on Amyloidosis laboratory findings
Amyloidosis laboratory findings in the news
Blogs on Amyloidosis laboratory findings
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Amyloidosis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[3]

Overview

Laboratory findings depend on the organs involved. Laboratory testing of specific organs can reveal dysfunction, and the degree of laboratory derangement is usually related to the extent of amyloid involvement.

Laboratory Findings

Cardiac

Cardiac biomarkers are the most important predictors of outcome in amyloidosis.
They provide a quantitative assessment for cardiac damage and wall strain.^[1]
The biomarkers include:

Troponin I or Troponin T
BNP and NT-proBNP

Hepatic

Liver function tests, including:

AST
ALT
Total bilirubin
Alkaline phosphatase
Albumin

Renal

A variety of kidney function tests can suggest amyloidosis.
These tests include abnormalities in:

Serum creatinine
Urinary protein
Glomerular filtration rate
Albumin to creatinine ratio in the urine

Thyroid

Common tests that are abnormal in thyroidal involvement of amyloidosis include:

TSH
Free T4

Bone marrow

Concurrent multiple myeloma can be found in patients with amyloidosis.
In such cases, laboratory testing should include^[2]:

References

↑ Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.
↑ Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR; et al. (2013). "Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis". J Clin Oncol. 31 (34): 4319–24. doi:10.1200/JCO.2013.50.8499. PMC 4881366. PMID 24145344.

Template:WH Template:WS

[pmid21483018-1] Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.

[pmid24145344-2] Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR; et al. (2013). "Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis". J Clin Oncol. 31 (34): 4319–24. doi:10.1200/JCO.2013.50.8499. PMC 4881366. PMID 24145344.

[1]

[2]